Granulation Endpoint Study Protocol and Data Sheet

Last reviewed 12 Nov 2026 · 9 min read

Contents
  1. Purpose and scope
  2. Study protocol: plan before running
  3. 1. Define the question and intended use
  4. 2. Connect the endpoint to product quality
  5. 3. Select candidate endpoint indicators
  6. 4. Design the study
  7. 5. Execute and analyse
  8. Protocol and data sheet template
  9. Run-level data sheet
  10. Filled fictional example row
  11. Common mistakes
  12. Frequently asked questions
  13. Does ICH Q8(R2) require a particular granulation endpoint method?
  14. Can the same endpoint be used for different products or scales?
  15. Should the study use torque, power, moisture or particle size?
  16. How long should batch-related study records be kept?
  17. References
  18. Related reading

In short: A granulation endpoint study establishes how a product-specific granulation process will recognise and control the intended endpoint. ICH Q8(R2) §2.3 identifies granulation endpoint as an example of a critical process parameter that a development programme may need to monitor or control. The guideline does not set a universal endpoint signal, moisture limit, mixing time or acceptance range, so the study must build its conclusion from product and process data.

Purpose and scope

Granulation changes the properties of a powder blend so that the resulting granules can support later manufacturing steps. Depending on the formulation and process, an endpoint may be inferred from a measured signal, a defined test on a sample, or a justified combination of observations. A fixed mixing time alone may not capture changes in raw materials, equipment, scale or operating conditions.

ICH Q8(R2) §2.3 says process development studies should support process improvement, validation and process control, and that development programmes should identify critical parameters to monitor or control, giving granulation endpoint as an example. It also discusses measurement systems for monitoring critical attributes or process endpoints. It does not tell every manufacturer which signal or test to use. Treat the protocol below as a study-planning template. The approved master production instructions and product-specific development knowledge govern routine manufacture.

For equipment context, see the rapid mixer granulator SOP and oscillating granulator SOP. Downstream performance may also relate to tablet compression critical quality attributes and the broader process validation guide.

Study protocol: plan before running

1. Define the question and intended use

Write a short study question, such as: “Which measurable endpoint signal, or combination of signals, consistently identifies the granule state that supports the intended downstream quality for this formulation and equipment?” State whether the work is exploratory development, endpoint method selection, process optimisation or confirmation of a proposed control strategy. Do not use a development study to change a registered or approved process without the applicable change and regulatory assessment.

Identify the formulation, development batch scale, equipment configuration, impeller and chopper details, binder preparation method, process stage and downstream steps that will be evaluated. Record the intended batch or study identifiers, material lots and the rationale for choosing the scale. A result from one product or machine should not be assumed to transfer automatically to another.

2. Connect the endpoint to product quality

List the product attributes that could be affected by under- or over-granulation. Depending on the product, these may include granule size distribution, moisture, flow, compressibility, tablet weight variation, hardness, friability, disintegration, dissolution or content uniformity. Choose endpoints based on the product’s development question and risk assessment; this list is illustrative, not a universal test panel.

Map possible material attributes and process parameters to the quality attributes. Potential factors could include starting material properties, binder amount or addition pattern, liquid addition rate, impeller or chopper settings, mixing profile and equipment geometry. The study should explain why selected factors matter and which are held constant. Do not treat a factor as critical merely because an instrument can measure it.

3. Select candidate endpoint indicators

Choose signals that can be collected consistently and interpreted scientifically. Options to evaluate may include motor torque or power, mixer current, a qualified process analytical technology signal, observation of the mass, or a sample-based test such as moisture or granule size. These are candidate approaches, not regulatory requirements. Confirm that the instrument is suitable, calibrated or qualified for its intended use, and that the method can distinguish meaningful changes in the relevant operating range.

If sampling is part of the endpoint method, define the sampling location, timing, sample handling, amount required by the analytical method and any precautions that prevent the sample from changing before testing. Decide how repeated measurements will be handled. A sample result should be connected to the corresponding process signal and elapsed process stage.

4. Design the study

Use development knowledge and risk assessment to choose which process factors and endpoint conditions to explore. A one-factor-at-a-time comparison can be useful for an initial question, while a structured design may help evaluate interactions when several factors may influence quality together. ICH Q8(R2) describes scientific pharmaceutical development and risk-based understanding; it does not prescribe a study design, run count or fixed number of replicates.

Define in advance the planned runs, controls, data to collect, analytical methods, handling of deviations and approach to interpreting results. Set proposed ranges only when justified by prior knowledge, product requirements, equipment capability or study data. If an illustrative local threshold is shown for teaching, label it an example in-house criterion and do not present it as a general limit.

5. Execute and analyse

Record the actual sequence and timestamps for material charging, binder addition, mixing, sampling, endpoint call and discharge. Capture instrument identifiers, settings, material lot details, actual process readings, sample IDs, analyst and observations. Record interruptions, alarms, unusual appearance, deviations and any change from the protocol. Keep raw outputs linked to the summary dataset.

Plot the endpoint signal against elapsed process stage or time and compare it with relevant sample results and downstream quality data. Assess whether the proposed signal is repeatable, sensitive to the process change of interest and practical to use at the intended scale. Examine unexplained variability and unexpected outcomes instead of excluding them without a scientific reason. Decide whether the evidence supports a single measurement, combined indicator, sample-based confirmation or additional study.

Protocol and data sheet template

Complete this controlled study form before execution. Add rows when the formulation or process needs more factors. Blank cells below are for site entry; there are no default limits or set points.

FieldPlanned entryActual result / reference
Study title and protocol ID
Product, formulation and batch / study ID
Study purpose and question
Equipment ID, scale and configuration
Material names, lot IDs and relevant attributes
Candidate endpoint signal or method
Instrument ID and qualification / calibration reference
Critical quality attributes and analytical methods
Process factors to evaluate
Factors held constant and rationale
Planned run sequence and sample points
Proposed range and scientific rationale
Data handling and analysis plan
Deviation and unexpected-result handling
Conclusion, limitations and next step
Prepared / reviewed / approved by and dates

Run-level data sheet

Run IDMaterial / lotActual process settingsSignal readings with timeSample ID and resultDownstream quality resultObservation or deviation

Filled fictional example row

Fictional example data only — these values are made up for illustration, are not an in-house criterion for any product, and are not a regulatory limit. In a development run, a team logs a candidate mixer-power signal and paired moisture (loss on drying) samples of the wet mass at three process stages. The fictional results are: early stage, 2.8 kW and 6.2% moisture; middle stage, 3.5 kW and 8.9%; later stage, 3.7 kW and 9.1%. The team does not select the later reading simply because it is the largest. It compares signal behaviour with granule size and downstream tablet results across the planned runs, then documents whether the signal reliably identifies the product-specific quality state. These made-up values are not suitable as operating settings for another product or machine.

The conclusion should state what the data support, what remains uncertain, and whether additional runs or scale evaluation are needed. If a relationship is not repeatable, keep investigating; do not convert a weak trend into a release or process limit.

Common mistakes

  • Assuming endpoint means a fixed time. Time can be a process variable, but it should not be treated as the endpoint unless the product and process data justify that choice.
  • Using one signal without checking its meaning. A torque, power or current trace is only useful when its measurement system and relationship to relevant product attributes are understood.
  • Changing several factors without a plan. When input variables change together, it may be difficult to identify what explains an outcome. Define the study purpose and analysis approach before the run.
  • Choosing a limit after seeing the data. Define the proposed interpretation approach in advance. Explain any post hoc analysis and confirm conclusions with appropriate additional evidence.
  • Ignoring scale and equipment differences. Document differences in vessel geometry, impeller, drive, sensor location and batch scale. Assess whether the endpoint method remains meaningful at the intended scale.
  • Reporting only averages. Preserve individual readings, sample IDs, timestamps, raw instrument outputs and atypical results so another reviewer can understand the data.
  • Treating a study template as a production instruction. Routine controls belong in approved manufacturing documents and must reflect the applicable product and site requirements.

Frequently asked questions

Does ICH Q8(R2) require a particular granulation endpoint method?

No. ICH Q8(R2) §2.3 gives granulation endpoint as an example of a critical process parameter that a development programme may need to monitor or control. It does not prescribe a sensor, moisture limit, mixing time or acceptance range.

Can the same endpoint be used for different products or scales?

Do not assume so. Formulation, equipment, scale and process differences can affect the signal and the relationship to product quality. Document the evidence supporting the method and assess any transfer or scale change through the applicable quality system.

Should the study use torque, power, moisture or particle size?

Select indicators that answer the study question and can be measured reliably. An instrument signal may need confirmation against sample-based and downstream results. The appropriate combination depends on the product and available development evidence.

If records are production or control records specifically associated with a product batch, 21 CFR 211.180(a) requires retention for at least 1 year after the expiration date of the batch (or 3 years after distribution for certain exempt OTC products without expiry dating), and EU GMP Volume 4, Chapter 4 §4.11 requires batch documentation to be kept for 1 year after batch expiry or at least 5 years after certification of the batch by the Qualified Person, whichever is longer; apply any longer or product-specific period that governs the record. EU GMP Chapter 4 §4.12 treats critical raw data supporting a marketing authorisation separately, so follow the applicable retention schedule for development records.

References

  • International Council for Harmonisation, ICH Q8(R2): Pharmaceutical Development, current Step 4 version dated August 2009, especially §2.3, “Manufacturing Process Development”: official PDF.
  • European Commission, EudraLex Volume 4, Chapter 4: Documentation, revision 1, in operation 30 June 2011, §§4.11–4.12: official PDF.
  • 21 CFR Part 211, current eCFR text, §211.180(a): eCFR.

Related articles